[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ards\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ards":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,42,73,105,121,137,153,178,216,238,263,291,318,347,368,391,419,441,467,493,520,554,581,621,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644267","fibrinogen-to-albumin-ratio-as-a-predictor-of-acute-respiratory-distress-syndrome-in-traumatic-brain-injury-100644267",false,"NCT07664358","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Patients With Traumatic Brain Injury: The Prospective, Observational, Multi-center FARDS Study","FARDS","Inclusion Criteria:\n\n* Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury\n* Admission to the ICU within 24 hours of injury.\n* Patients will be expected to remain under hospital care for follow-up\n* Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission.\n* Informed consent will be obtained from a legally authorized representative.\n\nExclusion Criteria:\n\n* Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy.\n* Pre-existing ARDS on admission.\n* Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling.\n* Use of anticoagulant or fibrinolytic therapy before admission.\n* Active malignancy or severe systemic infection at admission.\n* Direct sever lung injury\n* Pregnancy\n* Refusal of consent","ALL","18 Years",{"count":21,"type":22},350,"ESTIMATED","OBSERVATIONAL","this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.",[26,27,28],"Fibrinogen Albumin Ratio","ARDS","TBI (Traumatic Brain Injury)","NOT_YET_RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":22},"2026-07-01",{"date":37,"type":22},"2026-12-30",{"name":39,"class":40},"Tanta University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100642234","self-directed-mobile-mindfulness-to-address-icu-survivors-psychological-distress-100642234","NCT07634419","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: Lift RCT (Lift 3)","Lift 3","Inclusion Criteria:\n\nInclusion criteria present during hospitalization\n\n1. Adult (age ≥18)\n2. Managed in an ICU for ≥24 hours during the time inclusion criterion #3 is met\n3. Serious acute cardiorespiratory condition, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n   * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented)\n   * urgent cardiac catheterization\n4. Cognitive status intact\n\n   o No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n5. Absence of severe and\u002For persistent mental illness\n\n   o Treatment for severe and\u002For persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys)\n\nInclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital):\n\n1\\. Elevated baseline psychological distress symptoms, defined as a PHQ-9 score ≥5\n\nExclusion Criteria:\n\nExclusion criteria present in the hospital:\n\n1\\. Discharged to a location other than a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility)\n\nExclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital):\n\n1. Severe psychological distress as assessed by endorsement of active suicidality (see Protection of Human Subjects document for study team management of this finding)\n2. Failure to randomize within 1 month after discharge from the hospital to home\n3. Failure to login to study app and access content within 2 weeks after randomization",{"count":51,"type":22},450,"INTERVENTIONAL",[54],"NA","Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.",[57,58,59,60,61,62],"Critical Illness","Heart Failure","Sepsis","Ards","Pneumonia","Trauma Injury","2026-06-12",{"date":65,"type":33},"2026-06-16",{"date":67,"type":22},"2026-06-01",{"date":69,"type":22},"2031-05-31",{"name":71,"class":40},"Duke University",3,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":52,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100570010","phase-2-just-breathe-breathing-life-into-innovative-therapies-for-ards--cohort-a-vilobelimab-100570010","NCT06701682","JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab","Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS)","Inclusion Criteria:\n\nThe following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.\n\n* ARDS Severity of moderate or severe based on PaO2\u002FFiO2 or SpO2\u002FFiO2 assessment at the time of randomization\n\nExclusion Criteria:\n\n* No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol NCT06703073.",{"count":81,"type":22},200,[83],"PHASE2","This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design.\n\nCohort A: Participants will be randomized to receive either a placebo or vilobelimab.\n\nThis record describes the default procedures and analyses for Cohort A. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.",[86,27,87,88],"Acute Respiratory Distress Syndrome (ARDS)","ARDS (Acute Respiratory Distress Syndrome)","Acute Respiratory Distress Syndrome",[90,91,27,88,92],"BARDA","JUST BREATHE","Acute Respiratory Failure","RECRUITING","2026-05-07",{"date":96,"type":33},"2026-05-08",{"date":98,"type":33},"2025-06-21",{"date":100,"type":22},"2028-09",{"name":102,"class":103},"PPD Development, LP","INDUSTRY",40,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":78,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":52,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":104},"100570009","phase-2-just-breathe-breathing-life-into-innovative-therapies-for-ards--cohort-b-paridiprubart-100570009","NCT06701669","JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart","Inclusion Criteria:\n\nThe following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073:\n\n\\- ARDS Severity of moderate or severe based on PaO2\u002FFiO2 or SpO2\u002FFiO2 assessment at the time of randomization.\n\nExclusion Criteria:\n\nThe following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.\n\n-Participant has a known allergy or known hypersensitivity to paridiprubart or its excipients, including polysorbate 80",{"count":81,"type":22},[83],"This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design.\n\nCohort B: Participants will be randomized to receive either a placebo or paridiprubart.\n\nThis record describes the default procedures and analyses for Cohort B. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.",[86,27,87,88],[90,91,27,88,92],{"date":96,"type":33},{"date":118,"type":33},"2025-06-10",{"date":100,"type":22},{"name":102,"class":103},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":78,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":52,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":136,"locationsCount":104},"100570117","phase-2-just-breathe-breathing-life-into-innovative-therapies-for-ards-master-record-100570117","NCT06703073","JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)","Inclusion Criteria:\n\n* Participant (or their Legally Authorized Representative (LAR)) provides informed consent and agrees to comply with protocol requirements\n* Participant is at least 18 years of age or older at the time of consent.\n* Participant with signs and symptoms of ARDS according to the Berlin definition of ARDS.\n\nNote that participants on noninvasive ventilation may be screened.\n\n* Participant of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception, from the time of screening through Day 28. Additional cohort-specific requirements may apply\n* Participant agrees to not participate in another investigational interventional study while participating in this study (i.e., through Day 90).\n\nExclusion Criteria:\n\n* Participant with ARDS or at risk of developing ARDS due to the following reasons: trauma, large volume aspiration, or transfusion.\n* Participant with pulmonary edema due to cardiogenic pulmonary edema\u002Ffluid overload or hypoxemia primarily attributable atelectasis, in the absence of a predisposing risk factor for ARDS.\n* Participant who demonstrates an improvement in oxygenation and ventilatory support 24 hours prior to or during screening up to randomization, such that per investigator clinical judgement, the participant is expected to have significant improvement in lung function over subsequent 24 hours regardless of additional interventions.\n* Participant is known to be pregnant, nursing, or with a positive (urine and\u002For serum test) pregnancy test.\n* Participant is anticipated to be transferred to another hospital which is not a study site within 72 hours.\n* Participant is not expected to survive for 72 hours.\n* Participant has been on invasive mechanical ventilation or ECMO for more than 48 hours for ARDS at the time of consent.\n* Participant has an underlying clinical condition where, in the opinion of the Investigator and based on their clinical judgement, it would be extremely unlikely that the participant would come off ventilation\n* Participant has severe COPD requiring continuous long-term home oxygen therapy or mechanical ventilation (noninvasive ventilation or via tracheotomy) except for CPAP or bi-level positive airway pressure used solely for sleep-disordered breathing.\n* Participant has interstitial lung disease or idiopathic pulmonary fibrosis requiring continuous chronic home oxygen therapy.\n* Participant has NY Heart Association Class IV congestive heart failure.\n* Participant has a known allergy to any study medication or any of its excipients.\n* Participant is receiving systemic immunosuppressive therapy for solid organ or hematopoietic cancer or transplant anti-rejection medication.\n\nNOTE: Patients on chronic low dose immunosuppressive therapy may be enrolled at the discretion of the investigator in consultation with the medical monitor.\n\n* Participant is undergoing active cancer systemic chemotherapy.\n* Participant received treatment with an investigational immunomodulator or immunosuppressant drugs within 5 half-lives or 30 days (whichever is longer) before randomization.\n* Participant with concurrent infections or history of the following:\n\n  1. Known active tuberculosis,\n  2. Known active Hepatitis B, or\n  3. HIV and a CD4 count less than 50 or a detectable viral load of \\>200 copies\u002FmL HIV RNA.\n* Participant received treatment with any other investigational drugs within 30 days prior to consent.\n* Participant had a history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within 28 days of screening or inadequate wound healing secondary to major thoracoabdominal surgery at the time of screening.\n* Participant is considered by the investigator, for any reason, to be an unsuitable candidate for the study.\n\nParticipant may have additional cohort-specific requirements.",{"count":128,"type":22},600,[83],"This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments.\n\nThis record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.",[86,27,87,88],[90,91,27,88,92],{"date":96,"type":33},{"date":118,"type":33},{"date":100,"type":22},{"name":102,"class":103},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":78,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":52,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":104},"100570008","phase-2-just-breathe-breathing-life-into-innovative-therapies-for-ards--cohort-c-bevacizumab-100570008","NCT06701656","JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab","Inclusion Criteria:\n\nThe following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.\n\n* ARDS Severity of mild, moderate or severe, based on PaO2\u002FFiO2 or SpO2\u002FFiO2 assessment at the time of randomization.\n\nExclusion Criteria:\n\nThe following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.\n\n* Participant has a known allergy or hypersensitivity to the active substance\u002Fexcipients, or Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies\n* Participant with established cirrhosis and Child-Pugh Score of 7 or greater\n* Participant was dialysis-dependent prior to hospitalization. Participant must have a urine dipstick for proteinuria \\\u003C 2+\n* The hospitalized participant has a history or currently experiencing the following:\n\n  1. Participant must not have an international normalized ratio (INR) \\>1.5 and\u002For aPTT \\>1.5 × upper limit of normal (ULN) within 7 days prior to initiation of study treatment for participants not receiving anticoagulation. For participants on full dose oral or parenteral anticoagulants for therapeutic purposes the INR and\u002For activated partial thromboplastin time (aPTT) must be within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the participant on a stable dose of anticoagulants for ≥ 2 weeks prior to initiation of study treatment.\n  2. Participant with recent serious hemorrhage or history of recent hemoptysis \\> 2 episodes (defined as ≥2.5 mL of bright red blood per episode) within 1 month of screening.\n  3. Participant with inadequately controlled hypertension (defined as systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg). Antihypertensive therapy is permitted to achieve these parameters.\n  4. Participant with a history of hypertensive crisis or hypertensive encephalopathy.\n  5. Participant with a history of Grade ≥ 4 venous thromboembolisms.\n  6. Participant with significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 3 months of study drug treatment.\n  7. Participant with history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or active gastrointestinal bleeding within 6 months of study drug treatment.\n  8. Participant with serious, non-healing wound, active ulcer, or untreated bone fracture.\n  9. Participant with history or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (ie, in the absence of therapeutic anticoagulation).\n  10. Participant with clinically significant cardiovascular disease including cerebrovascular accident or myocardial infarction within previous 6 months, unstable angina, congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication.\n  11. Participant with a platelet count of \\\u003C75×109\u002FL.\n  12. Participant with current or recent (\\\u003C10 days prior to initiation of study treatment) use of aspirin (\\>325 mg\u002Fday) or clopidogrel (\\>75 mg\u002Fday).\n  13. Participant is receiving a direct anticoagulant (DOAC) such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) without the availability of a reversal agent at the site.\n  14. Participant is receiving a DOAC such as betrixaban (Bevyxxa®) and edoxaban (Lixiana®) for which there is no approved reversal agent.",{"count":81,"type":22},[83],"This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design.\n\nCohort C: Participants will be randomized to receive either a placebo or bevacizumab.\n\nThis record describes the default procedures and analyses for Cohort C. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.",[86,27,87,88],[90,91,27,88,92],{"date":96,"type":33},{"date":150,"type":33},"2025-10-28",{"date":100,"type":22},{"name":102,"class":103},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":19,"enrollmentInfo":161,"targetDuration":4,"studyType":52,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100367724","clinical-decision-support-tool-in-pards-pilot-study-100367724","NCT04068012","Clinical Decision Support Tool in PARDS Pilot Study","A Computerized Decision Support Tool for Ventilator Management in Pediatric Acute Respiratory Distress Syndrome Pilot Study","Inclusion Criteria:\n\n* Children \\> 1 month of age and \\>44 weeks gestation and ≤ 18 years of age AND\n* Supported on mechanical ventilation with pulmonary parenchymal disease (i.e. Pediatric Acute Respiratory Distress Syndrome (PARDS)) with Oxygen Saturation Index (OSI) ≥ 5) or Oxygenation Index (OI) ≥ 4 AND\n* Who are within 72 hours of initiation of invasive mechanical ventilation AND\n* Who are anticipated to require \\>72 hours mechanical ventilation.\n\nExclusion Criteria:\n\n* Conditions on enrollment that preclude conventional methods of weaning (i.e., status asthmaticus, severe lower airway obstruction, bronchiolitis, critical airway, Extra Corporeal Life Support (ECLS), intubation for Upper Airway Obstruction, Do Not Resuscitate orders, severe chronic respiratory failure, spinal cord injury above lumbar region, cyanotic heart disease (unrepaired or palliated)) OR\n* Conditions precluding the use of permissive hypercapnia or hypoxemia (i.e. intracranial hypertension, severe pulmonary hypertension)\n* Primary Attending physician refuses to enroll the patient","1 Month",{"count":162,"type":22},180,[54],"Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS).\n\nThis will be accomplished by using CDS tools developed and deployed in Children's Hospital Los Angeles (CHLA) which are based on the best available pediatric evidence, and are currently being used in an NHLBI funded single center randomized controlled trial (NCT03266016, PI: Khemani). Without CDS, there is significant variability in ventilator management of PARDS patients both between and within Pediatric ICUs (PICUs), but clinicians are willing to accept CDS recommendations. The CDS tool will be deployed in multiple PICUs, targeting enrollment of up to 180 children with PARDS. Study hypotheses:\n\n1. The CDS tool in will be implementable in nearly all participating sites\n2. There will be \\> 80% compliance with CDS recommendations and\n3. The investigators can implement automatic data capture and entry in many of the ICUs\n\nOnce feasibility of this CDS tool is demonstrated, a multi-center validation study will be designed, which seeks to determine whether the CDS can result in a significant reduction in length of mechanical ventilation (LMV).",[166,167,60],"Ventilation Therapy; Complications","Ventilator-Induced Lung Injury","2026-04-09",{"date":170,"type":33},"2026-04-14",{"date":172,"type":33},"2020-12-01",{"date":174,"type":22},"2027-07-01",{"name":176,"class":40},"Children's Hospital Los Angeles",8,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":186,"maxAge":19,"enrollmentInfo":187,"targetDuration":4,"studyType":52,"phases":189,"briefSummary":191,"conditions":192,"keywords":203,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":41},"100607835","phase-1-influence-of-personalized-lung-volume-optimization-maneuver-on-lung-function-and-cardiac-performance-in-children-100607835","NCT07193719","Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children","Influence of a Personalized Lung Volume Optimization Maneuver on Lung Aeration and Cardiac Performance in Mechanically Ventilated Children","ILOCO","CHD study:\n\nInclusion Criteria\n\n* congenital heart disease\n* surgery with cardiopulmonary bypass\n\nExclusion Criteria:\n\n* single ventricle physiology\n* ECMO\u002FVAD\n* \\\u003C36weeks of gestational age\n* chronic lung disease\n* Endotracheal tube leak \\> 15%\n* lack of informed consent from parents.\n\nECMO study Inclusion Criteria\n\n* patients with respiratory failure on ECMO or at risk for ECMO\n* invasive ventilation\n\nExclusion Criteria:\n\n\\- severe lung hypoplasia or interstitial lung disease","0 Years",{"count":188,"type":22},80,[190,83],"PHASE1","The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial in\n\n1. study) children undergoing biventricular repair of their congenital heart disease (CHD) with cardiopulmonary bypass and\n2. study) in children with severe respiratory failure at risk for or need for ECMO.\n\nThe main questions it aims to answer are:\n\nMain hypotheses of CHD study: Does a standardized PEEP-Titration maneuver, to optimize end-expiratory lung volume improve:\n\n* cardiac performance\n* lung function\n\nDoes it make a difference in:\n\n* length of ventilation\n* ventilation\u002Fperfusion mismatch of the lung\n* need for vasopressor support?\n\nMain hypotheses of ECMO study:\n\nDoes a LVOM in children\u002Finfants with severe respiratory failure \u002FARDS\n\n* improve lung compliance and gas exchange\n* facilitate lung protective ventilation according to PALICC-2 guidelines\n* improve lung aeration and V\u002FQ-matching assessed with EIT\n\nDoes it make a difference in\n\n* need for ECMO\n* duration of ECMO runs\n* hemodynamics stability",[193,194,195,196,197,198,199,200,201,27,202],"Congenital Heart Disease","Cardiopulmonary Bypass","Cardiac Surgery","Mechanical Ventilation","Positive End-expiratory Pressure (PEEP)","Lung Volume","Lung Mechanics","Hemodynamic Changes","Children","ECMO",[204,205,206,27,202,207],"cardiopulmonary interactions","end-expiratory lung volume","PEEP titration","cardiopulmonary bypass","2026-04-05",{"date":168,"type":33},{"date":211,"type":33},"2025-12-05",{"date":213,"type":22},"2027-12-20",{"name":215,"class":40},"Charite University, Berlin, Germany",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100627163","machine-learning-prediction-of-mortality-after-prone-positioning-in-ards-100627163","NCT07445061","Machine Learning Prediction of Mortality After Prone Positioning in ARDS","A Machine Learning Model to Predict Mortality in Patients With Acute Respiratory Distress Syndrome After Prone Positioning","Inclusion Criteria:\n\n* Diagnosis of ARDS according to the Berlin definition \\[15\\];\n* Receipt of at least one session of prone position ventilation (PPV) during hospitalization;\n* Requirement for mechanical ventilation.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* PPV duration \\\u003C6 hours;\n* ICU length of stay \\\u003C24 hours;\n* Pregnancy;\n* Missing key clinical data.",{"count":224,"type":22},377,"Acute respiratory distress syndrome (ARDS) is a life-threatening condition with high mortality. Prone position ventilation (PPV) is an evidence-based therapy that improves oxygenation and survival in patients with moderate to severe ARDS; however, outcomes remain heterogeneous. Early identification of patients at high risk of mortality after PPV may improve clinical decision-making and individualized management.\n\nThis retrospective observational study aims to develop and validate a machine learning model to predict intensive care unit (ICU) mortality in ARDS patients receiving prone position ventilation. Clinical, laboratory, and treatment variables collected from ICU electronic medical records will be used to construct prediction models using multiple machine learning algorithms. The performance of these models will be evaluated and compared to identify the optimal model for mortality prediction.",[86,227,228,229,27],"Prone Position Ventilation","Machine Learning","ICU","2026-03-01",{"date":232,"type":33},"2026-03-03",{"date":230,"type":22},{"date":235,"type":22},"2026-05-01",{"name":237,"class":40},"Shanghai Zhongshan Hospital",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":52,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":41},"100529899","pilot-study-on-ha380-column-use-in-critically-ill-patients-receiving-extracorporeal-support-100529899","NCT06179771","Pilot Study on HA380 Column Use in Critically Ill Patients Receiving Extracorporeal Support.","HA380 Column Use in Critically Ill Patients Receiving Extracorporeal Support for Acute Critical Illness; a Prospective, Randomised, Interventional, Feasibility, Pilot Study (HACEC)","HACEC","Inclusion Criteria\n\n* Consent obtained\n* Male or Female, aged 18 years - 65 years.\n* Admitted with a diagnosis of sepsis (according to sepsis-3 definition), trauma, ARDS of infectious or non-infectious aetiology, trauma or after major surgery\n* Need for extracorporeal support and specifically renal replacement therapy (RRT) and\u002For ECMO.\n* Vasopressor or inotropic therapy requirement at the time of RRT or ECMO support\n* Within 72 hours of requiring extracorporeal support\n* At least one of:\n* CRP \\> 100 mg\u002FL (in the absence of immunosuppressive therapy\u002Fimmunomodulation)\n* Lactate \\>2 mmol\u002FL\n\nExclusion Criteria\n\n* The participant may not enter the trial if ANY of the following apply:\n* Unable to obtain consent.\n* Expected to die in the next 24 hours.\n* Pre-existing chronic kidney disease - requiring dialysis \u002FeGFR \\\u003C 30ml\u002Fmin\u002F1.73m2\n* Pre-existing severe respiratory failure - e.g., requiring home oxygen\u002F home nebulisers\u002F poor exercise tolerance\n* Chronic heart failure - NYHA class III and above\n* Pregnancy\n* Requirement for immediate immune modulation e.g., plasma exchange, high dose steroids , IV immunoglobulins (does not include vasoplegic dose of steroids or immune modulation for COVID 19)\n* Participants who have participated in another research trial involving an investigational product in the past 12 weeks.","65 Years",{"count":104,"type":22},[54],"Patients who are very ill either due to a severe infection, major organ injury, trauma or a major operation may require significant support with devices such as a dialysis machine for the kidneys or Extracorporeal Membrane Oxygenation (ECMO) for the heart and lungs. This is often due to a reaction of the body to the insult which is termed inflammation. The investigators would like to assess if the use of a device that can remove the agents driving this reaction can lead to a quicker recovery form the illness. The device is a blood filter called HA380 and it would be connected to either the dialysis machine or the ECMO circuit. The investigators want to assess the feasibility of conducting a study with the HA380 column. We will also evaluate if the use of the HA380 column has an effect on the time spent on dialysis or ECMO, time spent on the breathing machine, time spent requiring drugs to support blood pressure and time spent in the intensive care unit.",[251,27,252,253],"Acute Kidney Injury","Inflammation","Extracorporeal Circulation; Complications","2026-02-27",{"date":256,"type":33},"2026-03-02",{"date":258,"type":33},"2024-09-02",{"date":260,"type":22},"2026-10-31",{"name":262,"class":40},"University Hospitals, Leicester",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":52,"phases":273,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":290},"100466469","phase-3-extracellular-vesicle-treatment-for-acute-respiratory-distress-syndrome-ards-extinguish-ards-100466469","NCT05354141","Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial","Inclusion Criteria:\n\n1. Men and women aged 18-75 years of age\n2. Presence of the following criteria for moderate to severe ARDS as defined by the Berlin Criteria within 24 hours of the first infustion:\n\n   1. Onset within 7 days of known clinical insult or requiring increasing respiratory rate, increasing oxygen flows, or increased work of breathing, and\n   2. Bilateral lung opacities not fully explained by pleural effusions, atelectasis, or nodules, and\n   3. PaO2\u002FFiO2 (P\u002FF ratio) ≤ 200 mm Hg, and\n   4. Invasive or noninvasive ventilation with a minimum PEEP 5 cm H2O or minimum of continuous positive airway pressure (CPAP) 5 cm H2O, or High Flow Nasal Oxygen at ≥ 30 L\u002Fmin, and\n   5. Respiratory failure not fully explained by cardiac failure or fluid overload.\n\nExclusion Criteria:\n\n1. Lack of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy).\n2. Stated unwillingness to comply with all study procedures and availability for the duration of the study\n3. Vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent.\n4. Active malignancy requiring treatment within the last two years, with the exception of non-melanoma skin cancers.\n5. Major physical trauma in the last 2 days, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries, such that not one or more injury may be undiagnosed at time of screening.\n6. Duration of mechanical ventilation exceeds 3 days or 72 hours from diagnosis of ARDS.\n7. ALT or AST \\> 8 x Upper Limit of Normal (ULN).\n8. Documented history of cirrhosis.\n9. DNR order, as in electing not to receive chest compressions, cardiac defibrillation, cardiac drugs, or intubation.\n10. Moribund-expected survival \\\u003C 24 hours.\n11. Severe metabolic disturbances at randomization (e.g., ketoacidosis, pH \\\u003C 7.2)\n12. Patient currently connected to Extracorporeal Membrane Oxygenation at initiation of screening.\n13. If the candidate, either a male or female of reproductive potential, is unwilling to two methods of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. The required duration of usage of double method OR maintenance of abstinence must include the time from the beginning of the screening period until Day 61, day of withdrawal or early termination\n14. Use of investigational COVID-19 agents or any other investigational agents within 30 days prior to the first dose.","75 Years",{"count":272,"type":22},970,[274],"PHASE3","To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).",[88,27],[278,279,280,27],"ExoFlo","Extracellular Vesicles","Exosome","2026-02-20",{"date":283,"type":33},"2026-02-23",{"date":285,"type":33},"2022-07-01",{"date":287,"type":22},"2027-12-31",{"name":289,"class":103},"Direct Biologics, LLC",32,{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100556162","the-aps-phenotyping-study-100556162","NCT06521502","The APS Phenotyping Study","The ARDS, Pneumonia, and Sepsis (APS) Consortium: A Prospective Observational Study to Evaluate Phenotypes","Inclusion Criteria:\n\nTo be eligible for enrollment, a patient must meet all the following inclusion criteria at the time of the first study-specified biospecimen collection (Time 0):\n\n1. Age ≥ 18 years old\n2. Admitted (or planned to be admitted) to an intensive care unit (ICU) or other in-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasal cannula) are routinely provided (referred to as an \"eligible unit.\")\n3. Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least one of the two criteria below:\n\n   * New receipt of invasive mechanical ventilation, non-invasive ventilation, high flow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acute hypoxemia.\n\n     a. Patients who use chronic oxygen therapy are eligible to participate if they are receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm for hypoxemia) or are started on advanced respiratory support (invasive mechanical ventilation, non- invasive ventilation, or high flow nasal cannula).\n   * Receipt of intravenous infusion of a vasopressor medication for at least one hour.\n4. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) is attributed to an acute inflammatory condition, including but not limited to any of the following:\n\n   * Any infection including pneumonia.\n   * Aspiration pneumonitis.\n   * Pancreatitis.\n   * Auto-inflammatory condition such as:\n\n     1. Hemophagocytic lymphohistiocytosis.\n     2. Suspected acute rheumatologic or auto-immune disease with pulmonary or cardiovascular manifestations.\n     3. Suspected cryptogenic organizing pneumonia presenting acutely.\n     4. Suspected diffuse alveolar hemorrhage.\n     5. Suspected acute anaphylaxis.\n     6. Suspected acute pulmonary drug toxicity.\n\nExclusion Criteria:\n\nTo be eligible for enrollment, a patient must not meet any of the following exclusion criteria at the time of the first study-specified biospecimen collection (Time 0):\n\n1. Patient\u002Flegally authorized representative (LAR) declines participation.\n2. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) has been present for \\> 48 hours.\n3. Patient has been in an eligible unit (inclusion criterion #2) for more than 120 hours (five days).\n4. Patient is no longer expected to meet the acute cardiovascular or pulmonary organ dysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment.\n5. Patient desires comfort measures only.\n6. Patient is a prisoner.\n7. Patient had out-of-hospital cardiac arrest leading to this hospitalization.\n8. Residence immediately before this hospitalization in a long-term acute care facility.\n9. Presence of tracheostomy for respiratory failure.\n10. Home invasive mechanical ventilation or non-invasive ventilation (except patients with non-invasive ventilation prescribed as a treatment for a sleep disorder may participate).\n11. Suspected cause of the patient's acute cardiovascular and\u002For pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, or sepsis), including but not limited to the list below:\n\n    * Drug overdose (without aspiration, lung injury, pneumonia, or infection).\n    * Trauma (without aspiration, pneumonia, or infection).\n    * Chronic lung disease without suspected infection, aspiration, or inflammation.\n    * Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitial lung disease, neuromuscular respiratory failure.\n    * Status epilepticus.\n    * Acute pulmonary embolism.\n    * Acute decompensated heart failure.\n    * Diabetic ketoacidosis.\n    * Acute stroke or intracranial hemorrhage.\n    * Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis).\n    * Cytokine release syndrome due to chemotherapy.\n12. Inability or unwillingness to complete study-specified blood draws, for example, due to local policies about hemoglobin thresholds for research blood draws.",{"count":299,"type":22},4000,"The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and\u002F or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and\u002For pneumonia.",[27,59,61],[303,304,305,306,307,308],"acute respiratory distress syndrome","sepsis","pneumonia","phenotype","endotype","critical illness","2026-02-18",{"date":281,"type":33},{"date":312,"type":33},"2024-07-25",{"date":314,"type":22},"2029-04-30",{"name":316,"class":40},"Vanderbilt University Medical Center",20,{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":52,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":41},"100625506","hemodynamic-effects-of-lung-collapse-and-overdistension-during-ards-100625506","NCT07423520","HemodynamIc eFfects of Lung Collapse and overdIstension During ARDS","HemodynamIc eFfects of Lung Collapse and overdIstension in Patients With Moderate-to-seVEre Acute Respiratory Distress Syndrome: the HI-FIVE Physiologic Study","HI-FIVE","Inclusion Criteria:\n\n* acute respiratory failure with onset \\\u003C 1 week from a predisposing risk factor, such as pneumonia, non-pulmonary infection, trauma, transfusion, aspiration, or shock;\n* bilateral opacities on chest radiography and computed tomography or bilateral B lines and\u002For consolidations on lung ultrasound not fully explained by effusions, atelectasis, or nodules\u002Fmasses;\n* pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema\u002Ffluid overload, and hypoxemia\u002Fgas exchange abnormalities not primarily attributable to atelectasis;\n* PaO2\u002FFiO2 ratio ≤ 200 during invasive controlled mechanical ventilation;\n\nExclusion Criteria:\n\n* age \\\u003C18 years;\n* pregnancy;\n* signs of barotrauma or documented pneumothorax;\n* severe tachycardia (HR \\> 120 bpm) and severe lacticaemia (lac \\> 4 mmol\u002FL)\n* pre-existing decompensated heart failure (NYHA class 3-4 and\u002For documented left ventricular ejection fraction \\\u003C 35%);\n* contraindications to EIT placing (open chest wounds, presence of cardiac pacemaker);\n* intubation as a result of an acute exacerbation of chronic pulmonary disease;\n* contraindications to esophageal balloon placement (high bleeding risk, esophageal varices).",{"count":317,"type":22},[54],"The management ARDS relies on ventilatory strategies aimed at limiting ventilator-induced lung injury (VILI). The setting of PEEP is still subject of debate, as randomized clinical trials comparing standardized higher versus lower PEEP strategies failed to demonstrate a clear survival advantage. Only few studies explored the hemodynamic effects of various PEEP levels depending on lung recruitability. Furthermore, the role of PEEP-mediated lung collapse and overdistention on patients' hemodynamics has yet to be elucidated. In this physiologic study, the association between EIT-measured lung collapse and overdistention and cardiac function will be explored, accounting for the individual potential for lung recruitment, partitioned respiratory mechanics and cardiac preload responsiveness. Three PEEP levels will be tested in a randomized, crossover fashion: PEEP corresponding to the crossing point between lung collapse and overdistention, PEEP associated with low lung collapse, PEEP associated with low lung overdistention.",[27,330],"AHRF",[27,330,303,332,333,334,335,336,337,338],"PEEP","collapse","overdistention","hemodynamics","heart-lung interactions","mechanical ventilation","randomized crossover trial","2026-02-14",{"date":281,"type":33},{"date":342,"type":22},"2026-02-28",{"date":344,"type":22},"2027-05-01",{"name":346,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":52,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":4},"100559444","phase-2-fostamatinib-for-treating-acute-respiratory-distress-syndrome-ards-in-hospitalized-adults-100559444","NCT06564207","Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults","Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study for the Long Term Evaluation of Fostamatinib for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome (ARDS)","FOSTA-ARDS","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Subject (or legal representative) provides informed consent to study participation.\n* Subject (or legal representative) understands and agrees to comply with planned study procedures.\n* Hospitalized with acute respiratory failure from ARDS with ratio of partial pressure of arterial oxygen to fraction of inspired oxygen PaO2\u002FFiO2 of 200 mm of Hg or less with positive end expiratory pressure (PEEP) equal to or higher than 5 cm of H2O and requiring invasive mechanical ventilation or extracorporeal support.\n* Functional respiratory imaging (FRI) compatible CT scan of the chest within the prior 7 days.\n* Duration of invasive mechanical ventilation \\\u003C 10 days.\n* Females of childbearing potential must agree to be abstinent or seek a highly effective form of contraception from the time of enrollment through 30 days after the last day of study drug.\n\nExclusion Criteria:\n\n* Severe hepatic impairment (Child-Pugh Class C).\n* Abnormal liver function tests (AST or ALT \\> 3x ULN or AST or ALT \\> 3x ULN)\n* Pregnant or nursing.\n* Participation in any other clinical trial, or receipt of an investigational medicinal product within 30 days prior.\n* Known concomitant life-threatening disease with a life expectancy \\\u003C 6 months.\n* Known hypersensitivity to fostamatinib.\n* Uncontrolled hypertension (Systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg).\n* Neutrophil count \\\u003C 1000\u002FuL\n* Death expected within 72 hours\n* Received a live vaccine in the last 30 days\n* Those who were cognitively impaired or mentally disabled prior to acute illness\n* Patients with acute coronary syndrome, ejection fraction \\\u003C30%, or active unstable arrhythmias",{"count":104,"type":22},[83],"This study is designed to evaluate the safety and efficacy of fostamatinib in hospitalized adult participants with acute respiratory distress syndrome (ARDS).",[88,27],"2026-01-30",{"date":361,"type":33},"2026-02-02",{"date":363,"type":22},"2026-08-30",{"date":365,"type":22},"2027-10-31",{"name":367,"class":40},"Inova Health Care Services",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":52,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":41},"100620816","enteral-nutrition-delivery-in-prone-position-ventilated-patients-with-moderate-to-severe-ards-100620816","NCT07362537","Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS","Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe Acute Respiratory Distress Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ARDS patients who meet the Berlin criteria for ARDS and have a P\u002FF ratio ≤ 200mmHg.\n* Patients receiving invasive mechanical ventilation and clinically judged to require prone ventilation, with an anticipated daily prone positioning time of ≥12 hours and a duration of prone ventilation therapy of ≥3 days.\n* Patients planned to receive enteral nutrition.\n* Age ≥18 and ≤85 years.\n* Consent to sign an informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to enteral nutrition, such as severe intestinal ischemia, active upper gastrointestinal bleeding, high-output intestinal fistula without a distal feeding route, abdominal compartment syndrome, severe diarrhea, intestinal obstruction, etc.\n* Presence of shock with hemodynamic instability (norepinephrine or equivalent vasopressor dosage ≥0.5ug\u002Fkg.min) or tissue hypoperfusion (lactate \\>3mmol\u002FL).\n* Life-threatening hypoxemia, hypercapnia, and acidosis.\n* Inability to tolerate prone ventilation (e.g., pregnant women, limb contractures, recent fractures, recent thoracic or abdominal surgery, pacemaker insertion within 48 hours, spinal instability, pelvic fractures, facial fractures, anticipated difficult airway).\n* Conditions preventing nasogastric or nasojejunal tube placement (e.g., esophageal rupture, severe esophageal varices).\n* Anticipated inability to start enteral nutrition within 48 hours.\n* Use of prokinetic agents within 48 hours prior to starting enteral nutrition.\n* Enteral nutrition via gastrostomy or jejunostomy.\n* Expected ICU stay or survival time less than 3 days.\n* Patients refusing further resuscitative treatment.\n* Pregnant or breastfeeding women.\n* Patients already enrolled in other interventional clinical studies or deemed unsuitable for the study by the clinician.","85 Years",{"count":104,"type":22},[54],"This pilot study is aimed to compare and assess the impact, safety, and practical utility of gastric versus postpyloric feeding in moderate to severe ARDS patients with prone position ventilation. Patients included will be randomly assigned to receive enteral nutrition either through a nasogastric tube or a nasojejunal tube. The primary endpoint is the achievement of enteral nutrition goals. Secondary endpoints include the incidence of hospital-acquired infections, the number of ventilator-free days within 28 days, ICU length of stay, ICU mortality, 28-day mortality, 60-day mortality rates, the incidence of enteral nutrition intolerance, and the rate of enteral nutrition intake.",[27],[27,381,382],"prone position ventilation","enteral nutrition","2026-01-16",{"date":385,"type":33},"2026-01-23",{"date":387,"type":22},"2026-01-20",{"date":260,"type":22},{"name":390,"class":40},"Southeast University, China",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":52,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100359710","careful-ventilation-in-acute-respiratory-distress-syndrome-covid-19-and-non-covid-19-100359710","NCT03963622","Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)","Careful Ventilation in Acute Respiratory Distress Syndrome","CAVIARDS","Inclusion Criteria:\n\n1. Age ≥ 18 y\n2. Moderate or severe ARDS (PaO2\u002FFiO2 ≤ 200 mmHg) within 48 h of meeting Berlin ARDS criteria (Patients who were eligible at the time of screening and whose PaO2\u002FFiO2 became \\> 200 mm Hg under prone positioning when starting the protocol remained eligible)\n\nExclusion Criteria:\n\n1. Received continuous mechanical ventilation \\> 7 days\n2. Known or clinically suspected elevated intracranial pressure (\\>18mmHg) necessitating strict control of PaCO2\n3. Known pregnancy\n4. Broncho-pleural fistula\n5. Severe liver disease (Child-Pugh Score ≥ 10)\n6. BMI \\>40kg\u002Fm2\n7. Anticipating withdrawal of life support and\u002For shift to palliation as the goal of care\n8. Patient is receiving ECMO at time of randomization",{"count":400,"type":22},740,[54],"This is a multicenter randomized controlled clinical trial with an adaptive design assessing the efficacy of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS).\n\nThe CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations. CAVIARDS consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (COVID-19 and non-COVID-19 patients). As per a typical basket trial design, the operational structure of both the COVID-19 substudy (CAVIARDS-19) and non-COVID-19 substudy (CAVIARDS-all) is shared (recruitment, procedures, data collection, analysis, management, etc.).",[27],[405,27,406,407,408,409],"Ventilation","Airway closure","Lung recruitment","COVID-19","Basket trial","2026-01-14",{"date":383,"type":33},{"date":413,"type":33},"2020-11-23",{"date":415,"type":22},"2026-09",{"name":417,"class":40},"Unity Health Toronto",33,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":52,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":41},"100615921","high-peep-in-noninvasive-ventilation-patients-with-pneumonia-or-ards-100615921","NCT07298889","High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS","Effect of High Versus Low Positive End-Expiratory Pressure on Intubation-Free Survival in Patients With Pneumonia or ARDS Receiving Noninvasive Ventilation: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18 years\n* PaO2\u002FFiO2 ≤300 mmHg or SpO2\u002FFiO2 ≤315（SpO2 ≤97%)\n* Anticipated NIV duration \\> 12 h\n* Preserved consciousness (GCS≥13)\n\nExclusion Criteria:\n\n* Use of NIV \\> 24 h before randomization\n* Acute-on-chronic respiratory failure\n* Congestive heart failure\n* Use of NIV after extubation (within 48 hours)\n* Contraindications to NIV (e.g., anatomical malformations, recent pulmonary\u002Fesophageal surgery \\[within 7 days\\])\n* Pneumothorax\n* NIV intolerance\n* Refusal to participate\n* Pregnancy\n* Need for emergency intubation",{"count":427,"type":22},706,[54],"Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.",[431,61,27],"Noninvasive Ventilation","2026-01-06",{"date":434,"type":33},"2026-01-07",{"date":436,"type":33},"2026-01-04",{"date":438,"type":22},"2029-12-31",{"name":440,"class":40},"Chongqing Medical University",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":41},"100605342","retrospective-cohort-study-of-low-flow-extracorporeal-carbon-dioxide-removal-ecco2r-system-evaluating-ecco2rs-efficacy-and-safety-in-participants-with-respiratory-failure-100605342","NCT07161271","Retrospective Cohort Study of Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) System: Evaluating ECCO2R's Efficacy and Safety in Participants With Respiratory Failure","Retrospective Cohort Study of Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) System: Evaluating Efficacy and Safety","Inclusion Criteria:\n\n* Patients supported with ECCO2R in one of the designated study sites\n* Admitted to the ICU between 1 Jan 2022 and 30 June 2024\n\nExclusion Criteria:\n\n* Patients younger than 18 years old",{"count":449,"type":22},59,"This is an observational study performed by retrospective review of data routinely collected for patients receiving low-flow extracorporeal carbon dioxide removal (ECCO2R) therapy in intensive care units (ICUs). Our aim is to firstly, describe the local practice in terms of patient selection and technical details of clinical management related to the use of low-flow ECCO2R system, and secondly, the clinical results in terms of patient outcomes and adverse events. These findings may allow clinicians to improve the quality and safety of ECCO2R therapy provision in the ICU.",[452,229,453,27],"Respiratory Failure","Asthma (Diagnosis)",[455,229,456,27,457],"ECCO2R","Asthma","Respiratory failure","2025-12-22",{"date":460,"type":33},"2025-12-23",{"date":462,"type":33},"2024-11-01",{"date":464,"type":22},"2027-06-30",{"name":466,"class":40},"Hong Kong University",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":375,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":476,"conditions":477,"keywords":481,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":41},"100600697","the-effect-of-single-lung-ventilation-duration-on-postoperative-pulmonary-complications-in-thoracic-surgery-100600697","NCT07100860","The Effect of Single Lung Ventilation Duration on Postoperative Pulmonary Complications in Thoracic Surgery","Does Duration Matter? A Study on Single-Lung Ventilation Time and Pulmonary Complications in Thoracic Procedures","Inclusion Criteria:\n\nAge ≥18 years Undergoing thoracic surgery OLV planned during the procedure\n\nExclusion Criteria:\n\nPediatric patients Patients not requiring OLV Previous thoracic surgery",{"count":475,"type":22},134,"This observational study investigates the relationship between the duration of single-lung ventilation (SLV) and the incidence of postoperative pulmonary complications (PPCs) such as pneumonia, pneumothorax, hemothorax, acute lung injury, and acute respiratory distress syndrome (ARDS) in adult patients undergoing thoracic surgery. A total of 134 patients aged 18-85 years, scheduled for thoracic surgery requiring SLV, will be monitored. Data including SLV duration, perioperative parameters, and postoperative pulmonary outcomes will be analyzed.",[478,479,60,480],"Postoperative Pulmonary Complications","One Lung Ventilation","Postoperative Pulmonary Atelectasis",[482,483],"postoperative pulmonary complications","one lung ventilation","2025-12-10",{"date":486,"type":33},"2025-12-18",{"date":488,"type":33},"2025-01-01",{"date":490,"type":22},"2026-01-01",{"name":492,"class":40},"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":52,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":41},"100483723","vq-matching-variations-with-peep-in-ards-according-to-compliance-based-phenotypes-france-100483723","NCT05578742","V\u002FQ Matching Variations With PEEP in ARDS According to Compliance-based Phenotypes (France)","Effect of PEEP on Ventilartion\u002FPerfusion Ratios According to Different Phenotypes in Patients With ARDS (France)","MISMATCHED FR","Inclusion criteria:\n\n* intubated patients with moderate and severe ARDS (Berlin definition, PaO2\u002FFiO2 ≤200 mmHg at PEEP 5 cmH2O)\n* undergoing deep sedation\n* on controlled mechanical ventilation\n* between 24 hours and 5 days after intubation.\n\nExclusion criteria:\n\n* age \\\u003C18 years old; pregnancy\n* patient undergoing legal protection\n* contra-indications to EIT (e. g. severe chest trauma or wounds)\n* pneumothorax; patient undergoing ECMO\n* patient with BMI ≥35 kg\u002Fm2\n* hemodynamic instability with MAP \\\u003C60 mmHg despite vasopressors.",{"count":502,"type":22},50,[54],"This study aim to compare the effect of Positive End Expiratory Pressure (PEEP) on ventilation\u002Fperfusion mismatch in two phenotypes of patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS), characterized by their respiratory system elastance (Ers). Ventilation\u002Fperfusion mismatch will be assessed by Electrical Impedance Tomography (EIT).",[27],[507,508,509,510],"pulmonary perfusion","ventilation-perfusion mismatch","compliance","recruitability","2025-12-02",{"date":513,"type":33},"2025-12-08",{"date":515,"type":33},"2024-02-08",{"date":415,"type":22},{"name":518,"class":519},"University Hospital, Angers","OTHER_GOV",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":528,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":529,"targetDuration":531,"studyType":23,"phases":4,"briefSummary":532,"conditions":533,"keywords":539,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":41},"100484735","early-severe-illness-translational-biology-informatics-in-humans-100484735","NCT05591924","Early Severe Illness TrAnslational BioLogy InformaticS in Humans","Prospective Observational Study of Biology of Critical Illness","ESTABLISH","Inclusion Criteria:\n\n* Age ≥18 years old\n* ≤48h since ICU admission\n* ICU admission within 72h of presentation to the emergency department (ER)\n* Clinical critical illness suspected on the basis of any one of the following:\n\n  1. Altered mental status (GCS\\\u003C15)\n  2. Cardiovascular collapse (presence of any: Heart rate \\>90, systolic blood pressure \\\u003C90, presence of vasopressors, lactate \\>2.0)\n  3. Respiratory collapse (presence of any: respiratory rate \\>20, PaCO₂ \\\u003C32 mm Hg, supplemental oxygen, invasive or non-invasive ventilation)\n  4. Suspected severe infection (presence of any: temperature \\>38°C or \\\u003C36°C, white blood cell (WBC) count \\>12,000\u002Fmm³ or \\\u003C4,000\u002Fmm³, presence of 1 or more antibiotics at the time of ICU admission)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* \\>72h since ICU admission\n* Admission to ICU in patients \\>72h after the presentation to the ER\n* No evidence of critical illness (ICU admission due to bed-spacing)",true,{"count":530,"type":22},1000,"24 Months","Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and\u002For the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive.\n\nThe purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.",[59,27,57,534,535,536,537,252,538],"Neurocognitive Dysfunction","Shock, Septic","Ventilator Associated Pneumonia","Immune Suppression","SIRS",[540,59,27,252,541,542,543,544],"Critical Care","Immune responses","Neurocognition","Critical illness","Translational Biology","2025-10-01",{"date":547,"type":33},"2025-10-06",{"date":549,"type":33},"2024-04-26",{"date":551,"type":22},"2034-12-31",{"name":553,"class":40},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":52,"phases":564,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":4},"100390606","phase-1-evaluating-avm0703-for-treatment-of-covid-19-or-influenza-mediated-ards-100390606","NCT04366115","Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome","AVM0703","Inclusion Criteria\n\nPatients who meet all of the following criteria will be eligible to participate in the study:\n\n1. Age ≥18 years;\n2. Must have laboratory confirmed COVID-19;\n3. Must have moderate or severe, immediately life-threatening COVID-19 or Influenza (A or B), as follows:\n\n   a. COVID-19 patients with ARDS (Berlin Criteria) as demonstrated by:\n\n   i. Chest radiograph or CT scan showing bilateral opacities not fully explained by effusions, lobar\u002Flung collapse, or nodules;\n\n   ii. Respiratory failure not fully explained by cardiac failure or fluid overload; and\n\n   iii. Impaired oxygenation defined as Moderate (partial pressure of oxygen \\[PaO2\\]:fraction of inspired oxygen \\[FiO2\\] ratio 100 mm Hg to \\\u003C200 mm Hg with positive end-expiratory airway pressure \\[PEEP\\] \\>5 cm H2O) or Severe (PaO2:FiO2 ratio \\\u003C100 mm Hg with PEEP\\>5 cm H2O) on more than 2 arterial blood gases at least 6 hours apart within a 24 hour period;\n\n   b. Influenza (A or B) patients with ARDS (Berlin Criteria) as demonstrated by:\n\n   i. Chest radiograph or CT scan showing bilateral opacities not fully explained by effusions, lobar\u002Flung collapse, or nodules;\n\n   ii. Respiratory failure not fully explained by cardiac failure or fluid overload; and\n\n   iii. Impaired oxygenation defined as Severe (PaO2:FiO2 ratio\\\u003C100 mm Hg with PEEP \\>5 cm H2O) on more than 2 arterial blood gases at least 6 hours apart within a 24 hour period;\n4. Requires invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) despite standard of care rescue measures (eg, prone positioning, and\u002For PEEP ladder, and\u002For inhaled pulmonary vasodilators, and\u002For recruitment maneuvers and\u002For neuromuscular blockade);\n5. Females of childbearing potential must have a negative serum pregnancy test at screening;\n6. Females of childbearing potential and nonsterile males must agree to use medically effective methods of contraception from the time of informed consent through 1 month after study drug infusion; and\n7. Capable of providing informed consent, or if not capable, a legally authorized representative is capable of providing informed consent\n\nExclusion Criteria\n\nPatients who meet any of the following criteria will be excluded from participation in the study:\n\n1. Moribund patient who, in the opinion of the Investigator, is not expected to survive at least 24 hours;\n2. Known hypersensitivity or allergy to the study drug or any of its excipients;\n3. D-dimer level \\>3 times above normal range;\n4. Known gastric or duodenal ulcer;\n5. Uncontrolled type 1 or type 2 diabetes, per judgment of the Investigator;\n6. Active and untreated bacterial, fungal, parasitic, or viral infection other than COVID-19 or Influenza (A or B). Patients with a history of a positive hepatitis B surface antigen and\u002For hepatitis B core antibody must have a negative hepatitis B polymerase chain reaction (PCR) assay result. Patients with history of a positive hepatitis C virus antibody test must have a negative hepatitis C PCR assay result;\n7. Positive testing for tuberculosis during screening;\n8. Known to have received a live vaccine within the previous 1 month;\n9. Immunocompromised patients, defined as those who have received a bone marrow or solid organ transplant on immunosuppressive therapy; or history of human immunodeficiency virus (HIV) infection who have not been taking anti retroviral therapy for at least 6 months before enrollment and\u002For with most recent CD4 count \\\u003C200 cells\u002FmL and\u002For most recent detectable viral load within the previous 6 months;\n10. Moderate to End-stage liver disease (Childs-Pugh Score \\>10);\n11. Dialysis-dependent due to underlying chronic renal disease. Note: patients who require dialysis for treatment of renal failure due to complications of COVID-19 or Influenza (A or B) infection are not excluded from enrollment;\n12. Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to the start of AVM0703 administration, including: angina requiring therapy, symptomatic peripheral vascular disease, New York Heart Association Class III or IV congestive heart failure, left ventricular ejection fraction \\\u003C30%, left ventricular fractional shortening \\\u003C20%, or uncontrolled Grade 3 hypertension (diastolic blood pressure \\[DBP\\] \\>100 mm Hg or systolic blood pressure \\[SBP\\] \\>150 mm Hg) despite antihypertensive therapy.\n\n    Note: patients with heart failure requiring medical support due solely to complications of COVID-19 infection are not excluded from enrollment;\n13. Significant screening 12-lead ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation\u002Fflutter, left bundle-branch block, second degree atrioventricular (AV) block type 2, third-degree AV block, Grade 2 bradycardia, or heart rate corrected QT interval using Fridericia's formula average of triplicate ECGs \\>450 ms;\n14. Manic-depressive disorder, schizophrenia, or a history of severe depression or substance abuse;\n15. Pregnant or breastfeeding;\n16. Concurrent enrollment in any other clinical study involving administration of a novel (ie, unapproved or not considered standard of care) investigational pharmacological agent(s). Concurrent enrollment in observational and device studies and studies involving administration of pharmacological agent(s) approved for other indications or considered emerging standard of care for treatment of COVID-19 (eg, hydroxychloroquine, remdesivir, low-dose dexamethasone), will be allowed if approved by the Sponsor;\n17. Treatment with standard of care or off-label treatments for COVID-19 (eg, remdesivir), not administered as part of a formal clinical study, where the first dose was initiated within 72 hours of study drug start; and\n18. Inability to obtain informed consent from the patient or legally authorized representative.",{"count":563,"type":22},16,[190],"This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.",[27,567,568],"Covid19","Influenza, Human",[27,570,571],"COVID19","Influenza","2025-09-29",{"date":574,"type":33},"2025-10-02",{"date":576,"type":22},"2026-12-01",{"date":578,"type":22},"2032-03-01",{"name":580,"class":103},"AVM Biotechnology Inc",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":270,"enrollmentInfo":588,"targetDuration":4,"studyType":52,"phases":590,"briefSummary":591,"conditions":592,"keywords":597,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":41},"100561711","hemodynamic-monitoring-and-fluid-responsiveness-in-venovenous-extracorporeal-membrane-oxygenation-vv-ecmo---hemodynamecmonitoring-vv-study-100561711","NCT06593717","Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - \"HemodynamECMOnitoring-VV Study\"","Validation of Techniques for Hemodynamic Monitoring and Prediction of Fluid Responsiveness in Patients Undergoing Venovenous Extracorporeal Membrane Oxygenation - A Prospective Diagnostic Accuracy Study (\"HemodynamECMOnitoring-VV Study\")","Inclusion Criteria:\n\n* Patient receiving VV-ECMO support\n* Age 18 - 75 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Conditions not allowing for passive leg raising maneuvers, e.g. \"open abdomen\", known or suspected elevation of intracranial pressure, recent leg or spinal trauma or orthopedic conditions not permitting leg raising\n* Known ischemic or hemorrhagic stroke within 3 months prior to study enrollment.\n\nSuspicion of raised intracranial pressure is defined as pupil divergence (if not yet further clarified radiographically\u002Fneurologically\u002Fophthalmologically) or signs detected in routine computed tomography scans (compressed or elapsed basal cisterns or midline shift \\> 5 mm.",{"count":589,"type":22},30,[54],"In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels. This allows the supply of oxygen-rich blood to the organs (brain, heart, lungs, kidneys, liver, intestines, etc.) to be maintained.\n\nContinuous monitoring of cardiac function and circulatory status (blood pressure, blood flow to organs) is very important in intensive care medicine in order to control the administration of circulation-supporting medication and infusions. Various devices are routinely used for this task. However, in the specific situation of ECMO treatment, the measurements of these devices could be affected due to the artificial circulation; outside the body.\n\nThe purpose of this study is therefore to test the accuracy of different methods of circulation monitoring during ECMO treatment.",[593,27,61,594,595,596],"ECMO Treatment","Intensive Care","Hemodynamic Monitoring","Fluid Responsiveness",[598,599,27,600,601,595,596,602,603,604,605,606,607,608,609,610,611,612],"VV ECMO","Extracorporeal Membrane Oxygenation","Intensive Care Medicine","Critical Care Medicine","Passive Leg Raising","Pulse Contour Analysis","Transpulmonary Thermodilution","Bioreactance","Pulse Pressure Variation","End-expiratory Occlusion Test","End-inspiratory Occlusion Test","Cardiac Output","LVOT VTI","Stroke Volume","Vena Cava Ultrasound","2025-09-23",{"date":572,"type":33},{"date":616,"type":33},"2024-05-03",{"date":618,"type":22},"2027-01",{"name":620,"class":40},"Medical University of Vienna",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":270,"enrollmentInfo":628,"targetDuration":4,"studyType":52,"phases":629,"briefSummary":630,"conditions":631,"keywords":632,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":635,"leadSponsor":636,"locationsCount":41},"100561714","hemodynamic-monitoring-and-fluid-responsiveness-in-venoarterial-extracorporeal-membrane-oxygenation-va-ecmo---hemodynamecmonitoring-va-study-100561714","NCT06593756","Hemodynamic Monitoring and Fluid Responsiveness in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) - \"HemodynamECMOnitoring-VA Study\"","Validation of Techniques for Hemodynamic Monitoring and Prediction of Fluid Responsiveness in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation - A Prospective Diagnostic Accuracy Study (\"HemodynamECMOnitoring-VA Study\")","Inclusion Criteria:\n\n* Patient receiving VA ECMO support\n* Age 18 - 75 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Conditions not allowing for passive leg raising maneuvers, e.g. \"open abdomen\", known or suspected elevation of intracranial pressure, recent leg or spinal trauma or orthopedic conditions not permitting leg raising\n* Known ischemic or hemorrhagic stroke within 3 months prior to study enrollment.",{"count":589,"type":22},[54],"In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels. This allows the supply of oxygen-rich blood to the organs (brain, heart, lungs, kidneys, liver, intestines, etc.) to be maintained. Continuous monitoring of cardiac function and circulatory status (blood pressure, blood flow to organs) is very important in intensive care medicine in order to control the administration of circulation-supporting medication and infusions. Various devices are routinely used for this task. However, in the specific situation of ECMO treatment, the measurements of these devices could be affected due to the artificial circulation; outside the body. The purpose of this study is therefore to test the accuracy of different methods of circulation monitoring during ECMO treatment.",[593,27,61,594,595,596],[598,599,27,600,601,595,596,602,603,604,605,606,607,608,609,610,611,612],{"date":572,"type":33},{"date":616,"type":33},{"date":618,"type":22},{"name":620,"class":40},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":645,"maxAge":4,"enrollmentInfo":646,"targetDuration":647,"studyType":23,"phases":4,"briefSummary":648,"conditions":649,"keywords":653,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":4},"100607132","electrical-impendance-tomography-usage-in-icu-100607132","NCT07184580","Electrical Impendance Tomography Usage in ICU","Electrical Impendance Tomography Usage in ICU : Registry Creation","EITICU","Inclusion Criteria for ICU Patients:\n\n* Patient aged more than 12 years old (no pediatric EIT belt)\n* Patient monitored by an EIT belt\n\nExclusion criteria Patient who expressed opposition to participate.","12 Years",{"count":530,"type":22},"2 Months","Electrical Impedance Tomography (EIT) is a non-invasive, radiation-free, bedside imaging technique that has been in clinical use for over three decades (1).\n\nIt is primarily utilized to monitor regional lung ventilation in mechanically ventilated patients. In recent years, EIT has become a routine tool in critical care settings due to its capacity to provide real-time, bedside insights into pulmonary function. Its applications are diverse, ranging from support during non-invasive ventilation and endotracheal intubation (2) to the management of complex cases of mechanical ventilation. One of its key advantages lies in guiding the optimization of Positive End-Expiratory Pressure (PEEP) titration, which may help tailor ventilatory support to individual patients and potentially reduce the mechanical power delivered to the lungs(3,4).\n\nDespite these benefits, current evidence does not conclusively demonstrate a reduction in mortality associated with the use of EIT in critical care (5,6). Nevertheless, EIT shows promise in several emerging areas, such as monitoring ventilation distribution during prone positioning - even in awake, non-intubated patients (7) - and in the early detection of atelectasis under various clinical conditions (8).\n\nRecently, advancements in EIT technology have led to the development of new models capable of assessing pulmonary \"pulsatility,\" thereby expanding the potential clinical applications of EIT beyond traditional ventilation monitoring. This feature may facilitate the bedside detection of conditions such as atelectasis, pneumonia, pleural effusion, and even pulmonary embolism (9,10).\n\nIn this context, the Intensive Care Unit at Erasme Hospital is acquiring two EIT devices to enhance diagnostic capabilities and improve the care of patients requiring either non-invasive or invasive ventilation during their ICU stay. To support the systematic implementation of these devices and enable future research, it is necessary to establish a registry documenting their clinical use within the ICU. This registry will serve as a foundation for tracking usage patterns, evaluating outcomes, and potentially contributing to future scientific studies.\n\nStandard ICU data such as SOFA scores and SAPS II will be recorded, as is already routinely done in some registries like Epimed.\n\nThis registry will be specific to the Erasme ICU and will collect detailed data on ventilation parameters, EIT measurements, and recruitment maneuvers in patients undergoing mechanical ventilation-whether invasive or non-invasive-when the clinical team determines that a recruitment maneuver is indicated and chooses to use an EIT device for monitoring.\n\nData will be entered into RedCap by the attending physicians or physiotherapists responsible for the patient.\n\nData collection will be prospective, as it is not technically possible to automatically synchronize the recording of ventilation parameters and EIT measurements using the existing software systems.\n\nThere are no expected risks for the patients, as the procedures involved are considered standard practice in intensive care settings.\n\nPatients may benefit from the collection of these data, as it allows for closer monitoring of ventilation parameters during their ICU stay.\n\nAs this is a registry-based study, there will be no predefined duration or fixed number of patients. However, we estimate data will be recorded over a five-year period, with an inclusion of at least 300 patients per year.\n\nInclusion Criteria for ICU Patients:\n\n* Patient aged more than 12 years old (no pediatric EIT belt)\n* Patient monitored by an EIT belt OR Patient undergoing a recruitment maneuver OR Patient undergoing prone position.",[27,650,651,652],"Alveolar Recruitment Manoeuvres","Prone Position","Electrical Impedance Tomography (EIT)",[27,654,655,656,657,658],"Recruitment manoeuvres","Prone positioning","PEEP optimization","EIT","Electrical impedance tomography","2025-09-17",{"date":661,"type":33},"2025-09-22",{"date":663,"type":22},"2025-10-15",{"date":665,"type":22},"2031-04",{"name":667,"class":40},"Erasme University Hospital"]